Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?
Author:
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine
Link
https://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvad049/50947055/pvad049.pdf
Reference16 articles.
1. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial;Talmor-Barkan;Eur Heart J Cardiovasc Pharmacother,2022
2. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: observations from the prospective EMIR Registry;Esteve-Pastor;Eur Heart J Cardiovasc Pharmacother,2022
3. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care;Kirchhof;Eur Heart J Cardiovasc Pharmacother,2022
4. Focus on different aspects of atrial fibrillation;Agewall;Eur Heart J Cardiovasc Pharmacother,2022
5. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48;Bonaca;Eur Heart J Cardiovasc Pharmacother,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3